Moderna stock rises on cancer vaccine data and fresh upgrades

Published on 09/18/2026 at 13:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moderna stock traded at USD 158.07 on September 17, 2026, with a market value of USD 63.11 billion. MarketBeat said July 31 revenue was USD 145.0 million and EPS was minus USD 1.97.

Isometrische 3D-Grafik zeigt Pharma-Wertschöpfungskette von Labor bis Krankenhaus — Moderna Inc. (US60770K1034) illustriert die isometrische Wertschöpfungskette der Biotech-Branche von Forschung bis zur finalen Auslieferung, Illustration mit AI erstellt.

Moderna Inc. (ISIN US60770K1079) stock traded at USD 158.07 on September 17, 2026, after a session high of USD 161.96 and a prior close of USD 145.62. The move came as investors kept reacting to the company's Phase 3 cancer vaccine readout and to higher price targets from Wall Street.

Phase 3 data still drives the tape

According to Invezz on September 17, 2026, Moderna and Merck said the Phase 3 INTerpath-001 trial involved more than 1,100 patients and the combination significantly improved recurrence-free survival. The same report said the readout was the first positive Phase 3 result for a personalized mRNA cancer vaccine.

That matters because the market is now treating oncology as more than a side story. Invezz also said Moderna's shares had gained more than 100 percent over the past month.

Wall Street resets expectations

According to Invezz on September 17, 2026, Argus Research raised Moderna to Buy and set a USD 180 price target, while Rothschild & Co cut its rating to Sell and lifted its target to USD 81. The same report said Moderna's consensus rating remained Hold, with an average target of USD 91.

MarketBeat said on September 17, 2026, that Moderna had an average rating of Hold and a consensus price target of USD 76.72. It also listed CLSA at Outperform, Citi at Neutral with a target raised from USD 41 to USD 60, and Barclays with a target raised from USD 48 to USD 125.

Revenue and earnings

MarketBeat said Moderna's July 31, 2026 quarterly results showed revenue of USD 145.0 million, up 2.1 percent from the same quarter last year, and earnings per share of minus USD 1.97 versus consensus of minus USD 2.03. The same report said net margin was minus 141.43 percent and return on equity was minus 28.30 percent.

For investors, that mix is the key tension: a sharply rerated stock on one side, and a still-loss-making quarterly profile on the other. MarketBeat also said analysts expect Moderna to post minus USD 6.09 EPS for the full year 2026.

Stock near its range

Moderna stock traded at USD 158.07 on September 17, 2026, versus a 52-week range of USD 22.28 to USD 176.66. MarketBeat also put market capitalization at USD 63.11 billion and volume at 19,084,286 shares.